A Single‐Center Experience on Outcomes of Complementary and Alternative Medicine Use Among Patients With Cirrhosis

Cyriac Abby Philips, Rajaguru Paramaguru, Philip Augustine, Sasidharan Rajesh, Rizwan Ahamed, Tom George, Guruprasad Padsalgi – 12 April 2019 – Drug‐induced liver injury (DILI) due to complementary and alternative medicine (CAM) use is on the rise throughout the world by patients looking for “safer” alternatives. However, data on acute‐on‐chronic liver failure (ACLF) due to CAM are lacking. In a large cohort of patients with cirrhosis, we retrospectively studied CAM‐related health‐seeking behavior and attempted to identify those who developed possible CAM‐DILI‐related ACLF.

Hepatology Highlights

Hirsh D. Trivedi, Daryl T.Y. Lau, Tasha B. Kulai, Harmeet Malhi, Robert E. Schwartz, Joseph F. Pisa, Robert S. Brown, Nicholas Russo, Kavitha M. Nair, Giorgio Roccaro, Petra Hirsova, Vikas Gupta, Xu Xu, Tibor Krisko, Enis Kostallari – 12 April 2019

Hepatology Highlights

Hirsh D. Trivedi, Daryl T.Y. Lau, Tasha B. Kulai, Harmeet Malhi, Robert E. Schwartz, Joseph F. Pisa, Robert S. Brown, Nicholas Russo, Kavitha M. Nair, Giorgio Roccaro, Petra Hirsova, Vikas Gupta, Xu Xu, Tibor Krisko, Enis Kostallari – 12 April 2019

Causes of hOCT1‐Dependent Cholangiocarcinoma Resistance to Sorafenib and Sensitization by Tumor‐Selective Gene Therapy

Elisa Lozano, Rocio I.R. Macias, Maria J. Monte, Maitane Asensio, Sofia Carmen, Laura Sanchez‐Vicente, Marta Alonso‐Peña, Ruba Al‐Abdulla, Patricia Munoz‐Garrido, Letizia Satriano, Colm J. O'Rourke, Jesus M. Banales, Matias A. Avila, Maria L. Martinez‐Chantar, Jesper B. Andersen, Oscar Briz, Jose J.G. Marin – 10 April 2019 – Although the multi‐tyrosine kinase inhibitor sorafenib is useful in the treatment of several cancers, cholangiocarcinoma (CCA) is refractory to this drug.

Hyperglycemia‐Triggered Sphingosine‐1‐Phosphate and Sphingosine‐1‐Phosphate Receptor 3 Signaling Worsens Liver Ischemia/Reperfusion Injury by Regulating M1/M2 Polarization

Yuanchang Hu, Chao Yang, Gefengqiang Shen, Shikun Yang, Xuyu Cheng, Feng Cheng, Jianhua Rao, Xuehao Wang – 10 April 2019 – Hyperglycemia aggravates hepatic ischemia/reperfusion injury (IRI), but the underlying mechanism for the aggravation remains elusive. Sphingosine‐1‐phosphate (S1P) and sphingosine‐1‐phosphate receptors (S1PRs) have been implicated in metabolic and inflammatory diseases. Here, we discuss whether and how S1P/S1PRs are involved in hyperglycemia‐related liver IRI.

Physicians’ Perspectives on Palliative Care for Patients With End‐Stage Liver Disease: A National Survey Study

Nneka N. Ufere, John Donlan, Lauren Waldman, Arpan Patel, Jules L. Dienstag, Lawrence S. Friedman, Kathleen E. Corey, Nikroo Hashemi, Peter Carolan, Alan C. Mullen, Michael Thiim, Irun Bhan, Ryan Nipp, Joseph Greer, Jennifer Temel, Raymond T. Chung, Areej El‐Jawahri – 9 April 2019 – Specialty palliative care (PC) is underused for patients with end‐stage liver disease (ESLD). We sought to examine attitudes of hepatologists and gastroenterologists about PC for patients with ESLD. We conducted a cross‐sectional survey of these specialists who provide care to patients with ESLD.

A Frizzled‐Like Cysteine‐Rich Domain in Glypican‐3 Mediates Wnt Binding and Regulates Hepatocellular Carcinoma Tumor Growth in Mice

Na Li, Liwen Wei, Xiaoyu Liu, Hongjun Bai, Yvonne Ye, Dan Li, Nan Li, Ulrich Baxa, Qun Wang, Ling Lv, Yun Chen, Mingqian Feng, Byungkook Lee, Wei Gao, Mitchell Ho – 9 April 2019 – Wnt signaling is one of the key regulators of hepatocellular carcinoma (HCC) tumor progression. In addition to the classical receptor frizzled (FZD), various coreceptors including heparan sulfate proteoglycans (HSPGs) are involved in Wnt activation. Glypican‐3 (GPC3) is an HSPG that is overexpressed in HCC and functions as a Wnt coreceptor that modulates HCC cell proliferation.

Subscribe to